View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 28, 2016

ObsEva begins Phase I clinical programme of OBE022 to treat pre-term labour

Swiss-based biopharmaceutical company ObsEva has commenced the Phase I clinical programme of OBE022 to treat pre-term labour.

Swiss-based biopharmaceutical company ObsEva has commenced the Phase I clinical programme of OBE022 to treat pre-term labour.

OBE022 is a first-in-class, orally active, small molecule prostaglandin F2alpha (PGF2alpha) receptor antagonist.

The trial will include 70 healthy volunteers to determine the safety and tolerability, pharmacokinetics and pharmacodynamics profile of OBE022 when administered in single ascending and multiple ascending oral dosages.

ObsEva chief scientific officer Jean-Pierre Gotteland said: "The first-in-human study programme is an important step towards the development of our first-in-class, orally active, PGF2alpha antagonist OBE022.

"The programme is designed for evaluating in healthy women the safety, tolerance and pharmacokinetics properties of OBE022, and will be essential for moving to Phase II in 2017."

“This further strengthens our advanced clinical stage product pipeline.

“The programme is designed for evaluating in healthy women the safety, tolerance and pharmacokinetics properties of OBE022, and will be essential for moving to Phase II in 2017."

Pre-term labour is a serious women's pregnancy health condition, resulting in a premature uterus contractions and causing a premature birth prior to 37 weeks of gestation.

PGF2alpha contracts the myometrium, a muscle tissue of womb, causing metabolites to rise in amniotic fluid before and during labour.

It also triggers enzymes to dilate the cervix and resulting to a membrane rupture.

OBE022 is designed to inhibit the PGF2alpha receptor, thereby safely controlling inflammation.

In previously conducted clinical studies, ObsEva has noted that OBE022 prevent spontaneous uterine contractions in pregnant rats without causing the adverse effects seen when compared with other prostaglandin synthesis inhibitors such as Indomethacin.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena